疏血通注射液联合阿替普酶溶栓治疗急性脑梗死患者的疗效及对IL-6、TNF-α、MMP-9水平的影响

doi:10.3969/j.issn.1671-7171.2024.08.022

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1223 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 This study aims to explore the efficacy of Shuxuetong injection combined with alteplase thrombolysis in treating patients with acute cerebral infarction and its effects on interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and matrix metalloproteinase-9 (MMP-9) levels. 【Methods】 One hundred patients with acute cerebral infarction were randomly divided into two groups, with fifty patients in each. The control group received alteplase thrombolysis alone, while the observation group received alteplase thrombolysis treatment combined with Shuxuetong injection. The efficacy, neurological function, daily living ability, hemorheological parameters before and after treatment, changes in IL-6, TNF-α, MMP-9, and C-reactive protein (CRP) levels, and the incidence of adverse reactions in both groups were compared. 【Results】 The total effective rate in the observation group was 92.00%(46/50), which was higher than 82.00%(41/50) in the control group (P<0.05). After treatment the hemorheological parameters in both groups were lower than those before treatment; And those parameters in the observation group were lower than those in the control group (P<0.05). Levels of IL-6, TNF-α, MMP-9, and CRP decreased after treatment in both groups, with even lower levels in the observation group compared to the control group (P<0.05). The National Institute of Health Stroke Scale (NIHSS) scores decreased, and Barthel Index scores increased post-treatment, with better scores in the observation group (P<0.05). No adverse reactions such as drug allergies, purpura, or bleeding occurred during the treatment in both groups. 【Conclusion】 Shuxuetong injection combined with thrombolytic therapy can effectively improve hemorheology, inhibit inflammation, and enhance vascular endothelial function in patients with acute cerebral infarction. Its efficacy is confirmed, and it is worth promoting in clinical applications.

Key words： Brain Infarction/DT Acute Disease Shuxuetong Zhusheye Tissue Plasminogen Activator Interleukin-6

Received: 20 January 2023

PACS:

R743.33

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Yafei
	YANG Qiang

Cite this article:

XU Yafei,YANG Qiang. Efficacy of Shuxuetong Injection Combined with Alteplase Thrombolysis in Treating Patients with Acute Cerebral Infarction and its Effects on IL-6, TNF-α, and MMP-9 Levels[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(8): 1195-1197.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.08.022 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I8/1195

[1] 刘雪云, 李坦, 梅春浩, 等. 合并脑小血管病的急性缺血性脑卒中患者静脉溶栓后出血转化及临床预后的研究进展[J].中华神经医学杂志, 2019, 18(5):481-486.
[2] 耿彪, 宋婷阁, 张鹏举,等. 血清炎症因子与老年急性脑梗死颈动脉粥样硬化及预后的关系[J].现代检验医学杂志, 2019,32(4):120-123.
[3] 黎炽辉, 卢云雁. 疏血通注射液治疗急性脑梗死的临床分析[J].中医临床研究, 2019,11(13):85-87.
[4] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志, 2015, 48(4):830-837.
[5] 高峰, 乔梵. 尿激酶和瑞替普酶溶栓治疗急性脑梗死的疗效观察[J].中国中西医结合急救杂志, 2018,25(5):499-502.
[6] 谈颂, 常思远, 宋波,等. 早期改良美国国立卫生研究院卒中量表评分对缺血性卒中预后的预测作用[J].中华神经科杂志, 2012, 45(3):154-157.
[7] SOLDATOVA O V, KUBYSHKIN A V, GORDIENKO A I, et al. Changes of nonspecific proteinases and proinflammatory cytokines in the clinical course of acute myocardial infarction of various severity[J].Kardiologiia,2018,5(3):5-12.
[8] 豆华明, 周红, 董超. 丹红注射液与疏血通注射液治疗急性脑梗死效果比较[J].实用中医药杂志, 2019,35(7):887-888.
[9] 刘婧. 疏血通注射液联合瑞舒伐他汀治疗急性脑梗死的效果观察[J].实用中西医结合临床, 2019,19(7):46-47.
[10] 齐献忠. 疏血通注射液联合尼麦角林治疗急性脑梗死的临床研究[J].现代药物与临床, 2019, 34(6):1683-1687.
[11] 杨佳, 邱占东, 邓刚, 等. 疏血通对脑梗死小鼠侧支循环形成及脑血管储备能力的影响[J].中华神经医学杂志, 2018, 17(1):10-18.
[12] 颜冬润. rtPA动脉溶栓联合疏血通注射液治疗急性脑梗死的临床研究[J].内蒙古中医药, 2016,11(7):54-55.
[13] 孙克保. 疏血通注射液对急性脑梗死患者血清NSE水平及功能恢复的影响[J].中西医结合心血管病电子杂志, 2015,3(33):80-81.
[14] 孙塑伦, 高颖, 孙建宁, 等. 疏血通注射液治疗缺血性脑血管病临床应用专家共识[J].中医杂志, 2018,59(2):175-179.